Primera bags $11m in series A:
This article was originally published in Clinica
Developer of gene expression analysis systems and assays Primera Biosystems has raised $11m in a series A financing round. Investors in the Providence, Rhode Island firm include MPM Capital, Burrill and Company and the Malaysian Technology Development Corporation. Primera said the funds will enable it to develop products based on its proprietary STAR (scalable transcription analysis routine) technology, which combines real-time PCR and DNA microarray technologies in one single system.
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.